Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

MRI imaging features for evaluating the efficacy and prognosis of TACE combined with targeted immunotherapy in unresectable hepatocellular carcinoma

European Journal of Radiology(2025)10.1016/j.ejrad.2025.112296Source: DataRank Database

MRI imaging features for evaluating the efficacy and prognosis of TACE combined with targeted immunotherapy in unresectable hepatocellular carcinoma is a research paper published in European Journal of Radiology (2025). On theSindex it has a DataRank of 0.208. It has been cited 3 times.

N/A

0.208DataRank · unranked

Scored on demand from live citation data

3 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 2.00)OA: hybridTopics (47)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.208

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (6)

Chen Lixun,Tang Langlang,Pan Xian,Wu Shaojie,Fang Zhuting

Live enrichment

PubMed:40680471 OpenAlex:https://openalex.org/W4412451556

National Key Research and Development Program of China

Grant: 2023YFC2413500

Fujian Provincial Health Technology Project

Grant: 2024ZD01004

FWCI

2.00

Citation Percentile

0.9%

Citation Trend

2025

2026

hybridLicense: cc-by

journalhttps://doi.org/10.1016/j.ejrad.2025.112296

publisherhttps://doi.org/10.1016/j.ejrad.2025.112296

publisherhttps://api.elsevier.com/content/article/PII:S0720048X25003821?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0720048X25003821?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/40680471

Fields of Study

Hepatocellular Carcinoma Treatment and PrognosisCholangiocarcinoma and Gallbladder Cancer StudiesOcular Oncology and TreatmentsCarcinoma, HepatocellularHumansRetrospective StudiesMultivariate AnalysisLogistic ModelsMagnetic Resonance ImagingChemoembolization, TherapeuticImmunotherapyMaleFemaleMiddle AgedAged

MeSH Terms

AdultAgedCombined Modality TherapyFemaleCarcinoma, HepatocellularHumansImmunotherapyLiver NeoplasmsMagnetic Resonance ImagingMaleMiddle AgedPrognosisRetrospective StudiesMultivariate AnalysisLogistic ModelsChemoembolization, TherapeuticTreatment Outcome

Keywords

MedicineHepatocellular carcinomaImmunotherapyCarcinomaMagnetic resonance imagingRadiologyOncologyInternal medicineCancerMRIOverall SurvivalProgression-free SurvivalMrecistLi-radsUnresectable Hepatocellular Carcinoma

Sustainable Development Goals

SDG 0: Good health and well-being